News of Note—HPV vaccination, Imutex's universal flu shot and more

non
In this week's news of note, healthcare providers are found to recommend HPV vaccine more often to girls than boys. (Pixabay)

Here is some other vaccine news of note for the week:

> A recent study found that healthcare providers are not recommending HPV vaccination to boys as often as to girls. ABC News article

> British firm Imutex’s universal flu vaccine candidate Flu-v turned in positive clinical results and could be available on England's NHS in two years. Daily Mail article

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Altimmune announced positive data from a phase 2a study of its monovalent NasoVAX intranasal flu vaccine. Results showed 100% seroprotection in the mid- and high-dose groups. Release

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.